AstraZeneca tosses another PhIII failure onto the scrap heap

John Carroll AstraZeneca just can't catch a break. After looking over lackluster late-stage results for its rheumatoid arthritis drug fostamatinib, the pharma giant has opted to ...

Continuing its manufacturing revamp, Pfizer unloads another Tennessee plant

Tracy Staton UPM's top leadership is familiar with the Bristol, TN, facility; CEO John Gregory started King Pharma back in 1994. FiercePharma News

Merck marks another failure in elusive hunt for Parkinson’s disease drugs

Ryan McBride Merck has cut one of most advanced efforts to develop a new therapy for Parkinson's disease. Its Phase III clinical trials of preladenant for the prevalent neurological ...

Jury is out in another case linking Novartis’ Zometa to jawbone death

Tracy Staton Novartis is one step closer to knowing how its latest round of Zometa litigation works out. After 11 days of testimony, the jury has started deliberating its verdict ...

Eli Lilly jettisons cancer contender after another Phase III failure

Ryan McBride The Indianapolis-based drug giant has slammed the brakes on development of enzastaurin, which failed to meet the main goal for boosting disease-free survival in a Phase ...

Celgene nabs another round of promising pivotal apremalist data for psoriatic arthritis

John Carroll FierceBiotech News

Minority Schering shareholders extract another €46 per share from Bayer

Eric Palmer A group of minority Schering AG shareholders held out to the bitter end against what Bayer wanted to pay them for their shares, and they will now get the sweet deal they ...

J&J grabs another “breakthrough” FDA win with early-stage cancer drug

John Carroll   Eight months after Johnson & Johnson committed to a $ 1.1 billion deal package to partner on Genmab's cancer antibody daratumumab, the FDA has blessed ...

U.K. likely to pay for Avastin despite another NICE rejection

Eric Palmer Regulators have again turned down Roche's ($ RHHBY) cancer drug Avastin for payment by the National Health System (NHS), this time for use on a recurrent, advanced ...

Roche sees another Rituxan biosimilar trial bite the dust

Ryan McBride Roche ($ RHHBY) faces one less potential copycat competitor to its blockbuster Rituxan franchise. The South Korea-based biotech Celltrion has nixed late-stage development ...

Dual-eligibles bill sets up another pharma fight over Medicare rebates

Tracy Staton Democratic lawmakers in both houses of Congress are backing a new bill extending Medicaid-style rebates to low-income Medicare patients, saying the provision would save ...
Page 7 of 7« First...34567
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS